Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients

Bibliography

• Chobanian AV, Bakris GL, Black HR, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560-72
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, The task force for the management of arterial hypertension of the European Society of Hypertension, the task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28(12):1462-536
   PubMed Web of Science ®Google Scholar
• Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62(3):443-62
   PubMed Web of Science ®Google Scholar
• Neutel JM. The role of combination therapy in the management of hypertension. Nephrol Dial Transplant 2006;21:1469-73
   PubMed Web of Science ®Google Scholar
• Zappe DH, Sowers JR, Hsueh WA, Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2008;10(12):894-903
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Derosa G, Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21(3):220-4
   PubMed Web of Science ®Google Scholar
• Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988 – 2008. JAMA 2010;303(20):2043-50
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290(21):2805-16
   PubMed Web of Science ®Google Scholar
• Devereux RB, de Faire U, Fyhrquist F, Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Curr Med Res Opin 2007;23(2):259-70
   PubMed Web of Science ®Google Scholar
• Jamerson K, Bakris GL, Dahlof B, ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007;16(2):80-6
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27(11):2121-58
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009;54(1):32-9
   PubMed Web of Science ®Google Scholar
• Deeks ED. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. Am J Cardiovasc Drugs 2009;9(6):411-18
   PubMed Web of Science ®Google Scholar
• Oparil S, Melino M, Lee J, Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010;32(7):1252-69
   PubMed Web of Science ®Google Scholar
• Destro M, Crikelair N, Yen J, Glazer R. Triple combination therapy with amlodipine, valsartan and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. Vasc Health Risk Manag 2010;6:821-17
   PubMedGoogle Scholar
• Wright RF, Duprez D, Purkayastha D, Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study. J Clin Hypertens (Greenwich) 2011;13(8):588-97
   PubMed Web of Science ®Google Scholar
• Laffer CL, Elijovich F. A critical appraisal of the clinical effectiveness of a fixed combination of valsartan, amlodipine, and hydrochlorothiazide in achieving blood pressure goals. Integr Blood Press Control 2011;4:1-5
   PubMedGoogle Scholar
• Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54(2):299-311
   PubMed Web of Science ®Google Scholar
• Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008;68(9):1239-72
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective randomized open blinded end-point. Blood Press 1992;1(2):113-19
   PubMedGoogle Scholar
• Parati G, Bosi S, Castellano M, Guidelines for 24-hour non invasive ambulatory blood pressure monitoring: report from a working group of the Italian Society of hypertension. High Blood Press 1995;4:168-74
   Google Scholar
• Novartis Pharmaceutical Corp. Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) tablets: US prescribing information (online). Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/022314lbl.pdf
   Google Scholar
• Fogari R, Zoppi A, Mugellini A, Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Adv Ther 2006;23(5):680-95
   PubMedGoogle Scholar
• Bhad P, Ayalasomayajula S, Karan R, Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. J Clin Pharmacol 2011;51(6):933-42
   PubMed Web of Science ®Google Scholar
• Cook NR, Cohen J, Hebert PR, Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995;155(7):701-9
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022-31
   PubMed Web of Science ®Google Scholar